NCT06554795View on ClinicalTrials.gov

First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

360

Participants

Timeline

Start Date

September 3, 2024

Primary Completion Date

February 28, 2027

Study Completion Date

February 28, 2027

Conditions
Solid Tumor, Adult
Interventions
DRUG

DB-1419

Administered Injection of Vein (I.V.)

Trial Locations (17)

2031

NOT_YET_RECRUITING

AUS01-0, Randwick

2109

NOT_YET_RECRUITING

AUS03-0, North Ryde

6009

RECRUITING

AUS02-0, Nedlands

19107

NOT_YET_RECRUITING

Site USA05-0, Philadelphia

20007

NOT_YET_RECRUITING

Site USA06-0, Washington D.C.

28078

NOT_YET_RECRUITING

Site USA03, Carolina

32827

NOT_YET_RECRUITING

Site USA02, Florida City

37203

NOT_YET_RECRUITING

Site USA07-0, Nashville

92663

NOT_YET_RECRUITING

Site USA08-0, Newport Beach

150001

NOT_YET_RECRUITING

Site CHN08-0, Harbin

200030

NOT_YET_RECRUITING

Site CHN06-0, Shanghai

471000

NOT_YET_RECRUITING

Site CHN03-0, Luoyang

08837

NOT_YET_RECRUITING

Site USA04-0, Edison

Unknown

NOT_YET_RECRUITING

Site CHN13-0, Changchun

NOT_YET_RECRUITING

Site CHN01-0, Shanghai

NOT_YET_RECRUITING

Site CHN05-0, Shanghai

NOT_YET_RECRUITING

Site CHN09-0, Zhengzhou

All Listed Sponsors
lead

DualityBio Inc.

INDUSTRY